Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity/mortality? Yes

Diabetes Care. 2009 Nov;32 Suppl 2(Suppl 2):S342-8. doi: 10.2337/dc09-S336.

Authors

Cristina Bianchi¹, Roberto Miccoli, Giuseppe Daniele, Giuseppe Penno, Stefano Del Prato

Affiliation

¹ Department of Endocrinology and Metabolism, Section of Diabetes and Metabolic Diseases, University of Pisa, Pisa, Italy.

No abstract available

Publication types

Review

MeSH terms

Administration, Oral
Cardiovascular Diseases / epidemiology*
Cardiovascular Diseases / mortality
Cardiovascular Diseases / prevention & control
Diabetes Mellitus / blood
Diabetes Mellitus / drug therapy
Diabetic Angiopathies / epidemiology*
Diabetic Angiopathies / mortality
Diabetic Angiopathies / prevention & control
Enzyme Inhibitors / therapeutic use
Glycoside Hydrolase Inhibitors
Humans
Hyperglycemia / complications
Hypoglycemic Agents / administration & dosage
Hypoglycemic Agents / therapeutic use*
Insulin / metabolism
Insulin Secretion
Metformin / therapeutic use
Myocardial Infarction / prevention & control
Sulfonylurea Compounds / therapeutic use
Thiazolidinediones / therapeutic use

Substances

Enzyme Inhibitors
Glycoside Hydrolase Inhibitors
Hypoglycemic Agents
Insulin
Sulfonylurea Compounds
Thiazolidinediones
Metformin